Thursday, January 17, 2013
A group of U.S. researchers has
developed inhibitors of the influenza
A virus matrix protein 2 mutant that is
responsible for resistance to amantadine.1 The first-generation inhibitor was widely
used for years to treat flu, but in 2006 the Centers for Disease Control and Prevention recommended against its use due to resistance. InfluMedix Inc.
has licensed the compounds and hopes to bring a new influenza antiviral to the
market within five years.
InfluMedix has licensed the compounds
and IP related to the proton channel structure. CEO Lidia Cristian said that
next steps include evaluating the compounds in animal models of influenza
infection to establish safety and efficacy.
Martz, L. SciBX 6(2); doi:10.1038/scibx.2013.27
Published online Jan. 17, 2013
1. Wang, J. et al.
Proc. Natl. Acad. Sci. USA; published online
Jan. 9, 2013; doi:10.1073/pnas.1216526110
Contact: William F. DeGrado, University of California, San Francisco,
Contact: Yibing Wu, same affiliation as above
2. Stouffer, A.L. et
al. Nature 451, 596-599 (2008)
AND INSTITUTIONS MENTIONED
Biota Pharmaceuticals Inc. (NASDAQ:BOTA), Rockville, Md.
Centers for Disease Control and Prevention, Atlanta, Ga.
Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568), Tokyo, Japan
Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif.
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K.
InfluMedix Inc., Radnor, Pa.
NanoViricides Inc. (OTCBB:NNVC), West Haven, Conn.
Northwestern University, Evanston, Ill.
(SIX:ROG; OTCQX:RHHBY), Basel, Switzerland
Temple University, Philadelphia, Pa.
University of California, San Francisco, Calif.
University of Pennsylvania, Philadelphia, Pa.